Evaluation of the therapies with mircera ® and conventional erythropoietin in patients with renal anemia. relationship and clinical outcomes
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Poster
- By: OLMOS, Virginia (Asociación Española, Montevideo, Uruguay)
- Co-author(s): Daners, Martín (Asociación Española, MONTEVIDEO, Uruguay)
Pignataro, Jorge (Roche, MONTEVIDEO, Uruguay)
OBJECTIVE To evaluate 1-year treatments using MirceraÂ® versus alpha erythropoietin in patients presenting chronic renal disease and anemia, seen from the patient's perspective. INTRODUCTION These patients lack erythropoietin, and consequently, they present with anemia. The EPO is administered in schedules requiring 3 weekly injections, while.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.